IP Library Granted Patent US 10,094,833
Granted Patent B2
US 10,094,833 · App. 15/502,711 · Granted Oct 9, 2018

Method and kit for detecting bacterial infection

Inventors: Clifford Taggart (Belfast, GB); Sinead Weldon (Belfast, GB); Chris Scott (Belfast, GB)
Assignee: Randox Laboratories Limited
G01N33/573C07K5/1021C07K16/40C07K2317/34G01N2333/96425G01N2800/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,094,833
App. No.
15/502,711
Granted
Oct 9, 2018
Kind
B2
Abstract

The invention relates to a novel antibody which binds to C-SLPI selected from the group consisting of SEQ ID NOs: 3 and 4.

Claims (6)

1. An immunogen comprising a polypeptide hapten of 5-12 amino acids in length comprising the structure Gln-Cys-Leu-Arg (SEQ ID NO: 10), wherein the N-terminus region of the polypeptide hapten comprises SEQ ID NO: 10; and wherein the polypeptide hapten is linked to an immunogenicity conferring carrier molecule by the C-terminal amino acid of the polypeptide hapten.

2. An antibody, or antigen binding fragment thereof, that is capable of specifically binding, to an epitope of C-terminal peptide fragment of Secretory leukocyte protease inhibitor (C-SLPI), the peptide fragment which is 10, 11 or 12 amino acids in length and comprises SEQ ID NO: 6 wherein the N-terminus region of the polypeptide fragment comprises SEQ ID NO: 6 and wherein the cross-reactivity of the antibody with full-length SLPI is <0.05%.

3. A method of determining an individual's C-SLPI level by:

(a) contacting an antibody specific for C-terminal fragment of Secretory leukocyte protease inhibitor (C-SLPI) with a sample from the individual; and

(b) detecting the amount of C-terminal fragment of Secretory leukocyte protease inhibitor (C-SLPI) in the sample;

wherein the cross-reactivity of the antibody with full-length Secretory leukocyte protease inhibitor (SLPI) is <0.05%.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVENYANCE PREVIOUSLY RECORDED AT REEL: 055950 FRAME: 0471. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Apr 20, 2021
From: RANDOX LABORATORIES LIMITED
To: NORTHERN BANK LIMITED
Reel/Frame 056210/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2021
From: RANDOX LABORATORIES LIMITED
To: NORTHERN BANK LIMITED
Reel/Frame 055950/0471 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2018
From: TAGGART, CLIFFORD; WELDON, SINEAD; SCOTT, CHRIS
To: RANDOX LABORATORIES LIMITED
Reel/Frame 046376/0034 →
Priority Claims (2)
GB 1414079.2 · Aug 8, 2014 · national
GB 1509564.9 · Jun 2, 2015 · national
Continuity (1)
Related Publication 20170212117A1 · Jul 27, 2017